Janney Montgomery Scott LLC acquired a new stake in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Rating) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 40,741 shares of the company's stock, valued at approximately $1,025,000. Janney Montgomery Scott LLC owned 0.66% of iShares Genomics Immunology and Healthcare ETF as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Westside Investment Management Inc. grew its holdings in iShares Genomics Immunology and Healthcare ETF by 200.0% during the third quarter. Westside Investment Management Inc. now owns 1,050 shares of the company's stock worth $21,212,000 after acquiring an additional 700 shares during the period. Vigilant Capital Management LLC acquired a new stake in iShares Genomics Immunology and Healthcare ETF during the fourth quarter worth about $25,000. Credit Suisse AG acquired a new stake in iShares Genomics Immunology and Healthcare ETF during the second quarter worth about $40,000. Finally, Flow Traders U.S. LLC acquired a new stake in iShares Genomics Immunology and Healthcare ETF during the third quarter worth about $303,000.
Get iShares Genomics Immunology and Healthcare ETF alerts:iShares Genomics Immunology and Healthcare ETF Stock Up 0.8 %
iShares Genomics Immunology and Healthcare ETF stock opened at $23.44 on Friday. The firm has a market cap of $145.33 million, a price-to-earnings ratio of 10.95 and a beta of 0.90. iShares Genomics Immunology and Healthcare ETF has a 52 week low of $22.09 and a 52 week high of $34.66. The business's 50-day moving average price is $23.62 and its 200 day moving average price is $25.59.
iShares Genomics Immunology and Healthcare ETF Company Profile
(Get Rating)
The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.
Further Reading
- Get a free copy of the StockNews.com research report on iShares Genomics Immunology and Healthcare ETF (IDNA)
- MarketBeat Week in Review – 4/24 – 4/28
- How to Invest in the Top Grocery Stocks for This Year
- Array Technologies Brings Solar Flare To 2023 Earnings Forecast
- Best Bank Stocks to Invest in Ahead of Rising Interest Rates
- How to Invest in Farmland: 7 Simple Ways
Want to see what other hedge funds are holding IDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Rating).
Receive News & Ratings for iShares Genomics Immunology and Healthcare ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Genomics Immunology and Healthcare ETF and related companies with MarketBeat.com's FREE daily email newsletter.
